ReviewFrontiers in oncology2025
A pan-cancer analysis targeting the oncogenic role of ATP-binding cassette transporter A1 in human tumors.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comprehensive Pan-Cancer Analysis of ABCA1: Insights From Multi-Omics Data and Exploratory Validation in Esophageal Squamous Cell Carcinoma.Cell biochemistry and function · 2026Article
- Integrative Multi-Omics Analysis Reveals HNRNPLL as a Potential Biomarker Associated with Hepatocellular Carcinoma Progression.Metabolites · 2026Article
- Lipid metabolic reprogramming in clear cell renal cell carcinoma: focus on high-density lipoprotein-related pathways.Oncology reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: ABCA1 is involved in the development and progression of a wide range of malignant tumors, so to further clarify the role of ABCA1 expression therein, and to search for new breakthroughs in the treatment of tumors and cancers, we launched a thorough pan-cancer analysis of ABCA1. Methods: Based on the manipulation of TCGA (The Cancer Genome Atlas), GEO (Gene Expression Omnibus), Human Protein Atlas (HPA) datasets and various bioinformatics tools, The oncogenic role of ABCA1 in 33 tumor types was explored from six aspects: gene expression, prognosis, variation, immunohistochemistry, correlation of tumor-associated fibroblastic infiltration, and enriched analysis of related genes. The potential value of ABCA1 was also mined, such as: ABCA1 may be a potential marker of tumor metastasis, play a role in cancer resistance, and its expression may inhibit the spread of tumor cells. Results: Based on the analysis results, we found that ABCA1 is expressed elevated and mutated in tumor samples of 33 cancer types compared with matched normal tissues, and these mutations may be related to the mechanism of cancer, metastatic ability, and prognosis, etc. Meanwhile, we also investigated the correlation between ABCA1 expression and tumor-associated fibroblast infiltration, and described its association with corresponding miRNAs, which can provide scientific basis for clinical diagnosis. Conclusions: Our study thoroughly illustrates the impact of ABCA1's systemic presence across various forms of cancer. Given its specificity to tumors, ABCA1 holds promise as a biomarker for cancer diagnosis, monitoring for recurrence, and predicting outcomes. Consequently, our research could significantly bolster the case for utilizing ABCA1 in the therapeutic approach to cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.